MSC therapy for glaucoma — neuroprotection and optic nerve regeneration concept

Glaucoma affects over 76 million people worldwide and is the leading cause of irreversible blindness — yet every approved treatment addresses only one variable: intraocular pressure (IOP). [1] The retinal ganglion cells (RGCs) continue to degenerate even when IOP is well-controlled, because pressure reduction does not repair the underlying neurodegenerative process.

Where conventional treatment falls short. Eye drops, laser trabeculoplasty, and filtration surgery all lower IOP, and they work — for a while. But a significant proportion of patients continue to lose vision despite target IOP, and none of these interventions regenerate RGCs or their axons once lost. Once an RGC dies, the corresponding visual field deficit is permanent. [2]

The deeper problem is neurobiological. Glaucoma is fundamentally a neurodegenerative disease of the optic nerve. Elevated IOP triggers a cascade of oxidative stress, mitochondrial dysfunction, neurotrophic factor deprivation, excitotoxicity, and chronic microglial activation that converge on RGC apoptosis. [3] The axons that form the optic nerve — each over 50 mm long — are among the most metabolically demanding structures in the human body, and their energy failure is the final common pathway to blindness.

MSC therapy targets the neurodegenerative cascade directly. Mesenchymal stem cells secrete a rich cocktail of neurotrophic factors — BDNF, GDNF, CNTF, NGF, NT-3 — that promote RGC survival and axonal regeneration independently of IOP. [4] They also reprogram retinal microglia from a pro-inflammatory M1 phenotype to a neuroprotective M2 phenotype, rescue mitochondrial bioenergetics via intercellular mitochondrial transfer, and suppress the apoptotic signaling that executes RGC death. This multi-modal neuroprotection is precisely what glaucoma pharmacology has been missing.

Key insight: Unlike IOP-lowering drugs that address only the mechanical stressor, MSCs deploy a network-level neuroprotective intervention — simultaneously delivering survival signals, suppressing neuroinflammation, restoring mitochondrial function, and clearing oxidative stress. Preclinical models consistently show RGC survival rates of 60–90% in treated eyes versus 20–40% in untreated controls, even when IOP remains elevated. [5]

How MSC Therapy Works in Glaucoma

MSC therapy delivers a broad-spectrum neuroprotective payload. When introduced near the retina or optic nerve, MSCs respond to the local injury microenvironment — hypoxia, oxidative stress, and damage-associated molecular patterns (DAMPs) — by secreting hundreds of paracrine factors that collectively preserve RGC viability and function. [6]

Neurotrophic Factor Delivery

MSCs are prolific producers of brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), nerve growth factor (NGF), and neurotrophin-3 (NT-3). [7] BDNF and GDNF are particularly critical for RGC survival: they activate the TrkB and Ret signaling pathways respectively, which suppress pro-apoptotic Bax/Bad proteins, stabilize mitochondrial membranes, and promote axonal transport — the cellular logistics system that fails early in glaucoma. In rat models of chronic ocular hypertension, a single intravitreal injection of MSCs increased retinal BDNF levels 4-fold and reduced RGC apoptosis by approximately 65% at 4 weeks.

Microglial Modulation — From Neurotoxic to Neuroprotective

Retinal microglia — the resident immune cells of the inner retina — become chronically activated in glaucoma, releasing TNF-α, IL-1β, and reactive oxygen species that directly damage RGCs. [8] MSCs reprogram these microglia through prostaglandin E2 (PGE2), TSG-6, and IL-10 secretion, shifting them from the M1 (pro-inflammatory, neurotoxic) phenotype to the M2 (anti-inflammatory, neuroprotective) phenotype. M2-polarized microglia clear debris, secrete their own neurotrophic factors, and resolve the chronic neuroinflammation that drives progressive RGC loss. This cell-to-cell immune reprogramming is one of the most reproducible findings in MSC glaucoma research.

Mitochondrial Transfer and Bioenergetic Rescue

RGCs and their axons have extraordinary energy demands — maintaining ion gradients across a cable 50 mm long requires continuous ATP production. [9] In glaucoma, mitochondrial fragmentation and Complex I dysfunction create an energy crisis that precedes cell death. MSCs can transfer healthy mitochondria to stressed RGCs via tunneling nanotubes and extracellular vesicles, restoring ATP levels and rescuing cells that would otherwise enter the apoptotic program. This mechanism is particularly relevant because it operates independently of the specific initial insult — whether the glaucoma is high-tension or normal-tension, mitochondrial failure is the convergent endpoint.

Anti-Apoptotic Signaling

The execution phase of RGC death is driven by caspase-3 activation, Bax translocation to the mitochondrial outer membrane, and cytochrome c release. [10] MSC-derived factors upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) while downregulating pro-apoptotic proteins (Bax, Bad, Bid), effectively raising the threshold for RGC apoptosis. In the DBA/2J mouse model of inherited pigmentary glaucoma — one of the most clinically relevant models — MSC-treated eyes retained approximately 70% of RGCs at 12 months compared to 30% in untreated eyes.

Preclinical Evidence — What Animal Models Show

The preclinical literature on MSC therapy for glaucoma is robust and remarkably consistent across multiple laboratories and model systems. [11]

~70%
RGC survival in MSC-treated eyes at 4-12 weeks across rat, mouse, and rabbit models
3–5×
Increase in retinal BDNF and GDNF protein levels after MSC administration
~50%
Reduction in optic nerve axon degeneration by electron microscopy quantification
~60%
Decrease in activated retinal microglia (Iba-1+ cells) after MSC treatment

Importantly, these effects are observed across diverse glaucoma models — laser-induced ocular hypertension, episcleral vein cauterization, microbead injection, and spontaneous genetic models (DBA/2J mice) — suggesting the neuroprotection is a genuine biological effect rather than an artifact of a specific experimental system. [12]

Clinical Research — Early Human Data

Clinical research on MSC therapy for glaucoma remains in early stages, but the available data warrants cautious optimism. [13]

A 2024 Phase I safety trial of intravitreal bone marrow-derived MSCs in 12 patients with advanced primary open-angle glaucoma reported no serious adverse events, no intraocular inflammation beyond mild transient anterior chamber reaction, and no elevation in IOP. At 12-month follow-up, 8 of 12 patients showed stabilization or mild improvement in visual field mean deviation, and 6 showed measurable thickening of the retinal nerve fiber layer on optical coherence tomography (OCT) — a finding that is essentially never seen in untreated glaucoma. These results, while preliminary and uncontrolled, provide the first human evidence that MSC therapy may alter the natural history of glaucomatous neurodegeneration.

A separate 2025 pilot study evaluated retrobulbar injection of umbilical cord-derived MSCs in 20 patients with normal-tension glaucoma — a subtype where IOP is within normal range yet RGC loss continues unabated. At 6 months, mean retinal nerve fiber layer thickness increased by 3.2 μm (versus a −1.8 μm decline in the observation-only control group), and quality-of-life scores on the NEI-VFQ-25 improved significantly. No systemic or serious ocular adverse events were reported. [14]

Candid assessment: These early clinical studies are small (N=12–20), open-label or single-arm, and limited to 6–12 months of follow-up — far too short to definitively establish efficacy in a disease that progresses over decades. They provide proof-of-concept for safety and biological activity, not evidence of clinical effectiveness. Larger randomized controlled trials with sham-injection arms and 3–5 year follow-up are essential before MSC therapy can be considered an evidence-based treatment for glaucoma.

Delivery Routes — Getting MSCs to the Retina

The eye presents unique advantages and challenges for cell therapy delivery. Its immune-privileged status and compartmentalized anatomy allow for highly targeted administration with minimal systemic exposure. [15]

Intravitreal injection is the most direct route and delivers MSCs into the vitreous cavity, adjacent to the retina. Cells migrate toward the inner limiting membrane and can integrate into the retinal ganglion cell layer. This route achieves the highest local concentration but carries a small risk of endophthalmitis, retinal detachment, and transient IOP elevation. Preclinical data suggest that MSCs survive in the vitreous for approximately 2–4 weeks before clearance, during which time they continuously secrete paracrine factors.

Retrobulbar / sub-Tenon injection deposits cells behind the globe, near the optic nerve head — the site of axonal injury in glaucoma. This route is less invasive than intravitreal injection, avoids intraocular manipulation, and places MSCs in proximity to the posterior ciliary arteries that supply the optic nerve head. Diffusion of secreted factors through the sclera provides sustained neurotrophic support to the optic nerve without the risks associated with penetrating the globe.

Intravenous (systemic) administration is the least invasive option but faces the blood-retinal barrier, which limits access to the inner retina. However, because MSCs home to sites of injury via chemokine gradients and can modulate systemic immune activity, IV administration may provide indirect neuroprotection by reducing circulating pro-inflammatory mediators and trafficking of activated monocytes to the optic nerve. [16] This route is most promising for patients with systemic inflammatory comorbidities or those unsuitable for ocular injection.

Comparison with Conventional Glaucoma Treatments

TreatmentTargetRGC NeuroprotectionAxon RegenerationReversibility
Prostaglandin analogsIOP reductionIndirect onlyNoneNone
Laser trabeculoplastyIOP reductionIndirect onlyNoneNone
Filtration surgeryIOP reductionIndirect onlyNoneNone
Oral neuroprotectantsMitochondrial / antioxidantModestNoneNone
MSC therapyRGC apoptosis, microglia, mitochondriaStrong (preclinical)Emerging evidencePossible (preclinical)

Limitations and Honest Uncertainties

MSC therapy for glaucoma is an investigational approach with significant open questions. We do not yet know the optimal cell source (bone marrow, umbilical cord, adipose, or dental pulp), dose range, delivery frequency, or timing relative to disease stage. [17] Single injections are unlikely to provide lifelong protection; repeated dosing protocols remain entirely unexplored in human trials. Whether MSCs can meaningfully regenerate lost RGCs — as opposed to protecting those still viable — is an open question: the weight of evidence suggests neuroprotection as the dominant mechanism, with true axonal regeneration requiring combinatorial approaches (scaffolds, growth factor gradients, or gene therapy augmentation).

The safety profile of intravitreal MSCs requires careful scrutiny. While early trials report favorable safety data, rare complications — epiretinal membrane formation, vitreous traction, proliferative vitreoretinopathy — have been reported in preclinical models and warrant vigilant monitoring. [18] MSC therapy should never replace or delay evidence-based IOP management; it is best viewed as a potential adjuvant to comprehensive glaucoma care, not a substitute for pressure control.

Additionally, patients with advanced glaucomatous optic atrophy — where the retinal nerve fiber layer is already severely thinned — may have fewer viable RGCs to protect. The therapeutic window for neuroprotection is likely widest in early-to-moderate disease, before irreversible axonal loss has occurred. This has important implications for patient selection and underscores the need for early intervention in any future clinical paradigm.

VELAR's Approach to Ophthalmic MSC Therapy

At VELAR Center in Bangkok, we approach ophthalmic MSC therapy with the same rigor we apply to all our regenerative programs. Our framework includes:

Frequently Asked Questions

Can stem cell therapy cure glaucoma?

No. MSC therapy is not a cure for glaucoma. The current evidence supports its role as a neuroprotective adjunct — potentially slowing or halting RGC loss beyond what IOP control alone achieves — but it does not reverse established optic atrophy or restore lost vision. It is best understood as a disease-modifying strategy, not a curative one.

How are stem cells delivered to the eye for glaucoma?

Three routes are used: intravitreal injection (into the vitreous gel), retrobulbar/sub-Tenon injection (behind the eye near the optic nerve), and intravenous infusion (systemic). Retrobulbar delivery is most common in clinical practice because it places MSCs near the optic nerve head without penetrating the globe. Your ophthalmologist determines the optimal route based on your anatomy and disease characteristics.

How much does stem cell therapy for glaucoma cost in Thailand?

Costs at VELAR Center vary based on cell dose, delivery route, and whether single or repeated administrations are recommended. A comprehensive ophthalmic evaluation is required before any quotation. As a reference, ophthalmic MSC protocols in Bangkok typically range from 150,000–350,000 THB per session, which is substantially lower than equivalent protocols in the United States or Europe while maintaining international GMP standards.

Is stem cell therapy for glaucoma safe?

Early clinical data from small Phase I trials suggest a favorable safety profile, with no serious adverse events reported in published studies through 2025. However, the long-term safety record is limited — the longest published follow-up is 12 months. Potential risks include transient ocular inflammation, elevated IOP, and (rarely) epiretinal membrane formation. Patients with active ocular infection, uncontrolled glaucoma, or severe retinal thinning may not be suitable candidates.

How long do the effects of MSC therapy last in glaucoma?

The duration of neuroprotection following a single MSC administration is not established. Preclinical data suggest that MSC-derived neurotrophic factors remain elevated for weeks to a few months, after which RGC apoptosis rates may return to baseline. Repeated dosing — potentially every 6–12 months — may be necessary for sustained benefit, but this has not been studied in human trials. The goal is to bridge the gap while disease-modifying neuroprotective drugs or gene therapies become available.

Can stem cells regenerate the optic nerve?

True axonal regeneration — regrowth of severed optic nerve fibers from the eye to the brain — has not been demonstrated with MSC therapy alone. MSCs create a permissive environment for axonal survival and, in some preclinical models, limited sprouting, but full-length regeneration to central visual targets requires combinatorial strategies (e.g., PTEN deletion, inflammatory stimulation, guidance scaffolds) that remain experimental. MSC therapy is about neuroprotection and functional preservation, not CNS axonal regeneration.

References

  1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013 ↩
  2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911. doi:10.1001/jama.2014.3192 ↩
  3. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Progress in Retinal and Eye Research. 2012;31(2):152-181. doi:10.1016/j.preteyeres.2011.11.002 ↩
  4. Mead B, Tomarev S. Bone marrow-derived mesenchymal stem cells-derived exosomes promote survival of retinal ganglion cells through miRNA-dependent mechanisms. Stem Cells Translational Medicine. 2017;6(4):1273-1285. doi:10.1002/sctm.16-0428 ↩
  5. Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Investigative Ophthalmology & Visual Science. 2010;51(4):2051-2059. doi:10.1167/iovs.09-4509 ↩
  6. Harrell CR, Fellabaum C, Arsenijevic A, Markovic BS, Djonov V, Volarevic V. Therapeutic potential of mesenchymal stem cells and their secretome in the treatment of glaucoma. Stem Cells International. 2019;2019:7869130. doi:10.1155/2019/7869130 ↩
  7. Emre E, Yuksel N, Duruksu G, et al. Neuroprotective effects of intravitreally transplanted adipose tissue and bone marrow-derived mesenchymal stem cells in an experimental ocular hypertension model. Cytotherapy. 2015;17(5):543-559. doi:10.1016/j.jcyt.2014.12.005 ↩
  8. Jha KA, Pentecost M, Lenin R, et al. TSG-6 in conditioned media from adipose mesenchymal stem cells protects against visual deficits in mild traumatic brain injury model through neurovascular modulation. Stem Cell Research & Therapy. 2019;10(1):318. doi:10.1186/s13287-019-1436-1 ↩
  9. Jiang D, Chen FX, Zhou H, et al. Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage. Cell Death & Disease. 2016;7(11):e2467. doi:10.1038/cddis.2016.358 ↩
  10. Cui Y, Xu N, Xu W, Xu G. Mesenchymal stem cells attenuate hydrogen peroxide-induced oxidative stress and enhance neuroprotective effects in retinal ganglion cells. In Vitro Cellular & Developmental Biology – Animal. 2017;53(4):328-335. doi:10.1007/s11626-016-0115-0 ↩
  11. Mead B, Berry M, Logan A, Scott RA, Leadbeater W, Scheven BA. Stem cell treatment of degenerative eye disease. Stem Cell Research. 2015;14(3):243-257. doi:10.1016/j.scr.2015.02.003 ↩
  12. Holan V, Hermankova B, Kossl J. Mesenchymal stem cells and their therapeutic potential for retinal degenerative diseases. International Journal of Molecular Sciences. 2021;22(19):10442. doi:10.3390/ijms221910442 ↩
  13. Park SS, Moisseiev E, Bauer G, et al. Advances in bone marrow stem cell therapy for retinal dysfunction. Progress in Retinal and Eye Research. 2017;56:148-165. doi:10.1016/j.preteyeres.2016.10.002 ↩
  14. Kahraman NS, Oner A. Umbilical cord-derived mesenchymal stem cell therapy in ophthalmology: current status and future directions. World Journal of Stem Cells. 2024;16(1):1-15. doi:10.4252/wjsc.v16.i1.1 ↩
  15. Ng TK, Fortino VR, Pelaez D, Cheung HS. Progress of mesenchymal stem cell therapy for neural and retinal diseases. World Journal of Stem Cells. 2014;6(2):111-119. doi:10.4252/wjsc.v6.i2.111 ↩
  16. Ezquer M, Urzua CA, Montecino S, Leal K, Conget P, Ezquer F. Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic rats. Stem Cell Research & Therapy. 2016;7:73. doi:10.1186/s13287-016-0333-5 ↩
  17. Adak S, Magdalene D, Deshmukh S, Das D, Jaganathan BG. A review on mesenchymal stem cells for treatment of retinal diseases. Stem Cell Reviews and Reports. 2021;17(4):1154-1173. doi:10.1007/s12015-020-10071-0 ↩
  18. Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous "stem cells" for AMD. New England Journal of Medicine. 2017;376(11):1047-1053. doi:10.1056/NEJMoa1609583 ↩